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The nation-wide 2-yearly breast-cancer screening pro- 
gramme in The Netherlands, for women aged 50-69, started 
around 1988, and was predicted to result eventually in a 16% 
reduction in breast-cancer mortality in the total female popula- 
tion. We present the results of screening up to January I, 1993, 
and compare these with the predicted results from the cost- 
effectiveness analysis, on which basis this mortality reduction 
had been calculated. At least 550,000 women aged 50-69 were 
invited to screening in 1990-1992, and 75% of these partici- 
pated. Cancer was suspected from 5, I62 examinations and 
further investigation was therefore required. Excision biopsy 
was done in 72% of referrals, and 2.515 breast cancers were 
detected. The results for 404,000 newly invited women com- 
pare favourably with expected values (in parentheses): 78% 
attendance rate (700/0), I .4% screen positive (I .6%). 6.8 can- 
cers detected per 1,000 women screened (6.4) and 38% of these 
cancers were DClS or invasive carcinomas smaller than I I mm 
in diameter (36%). More data, e.g., on treatment and interval 
cancers, will follow in the years to come. These first results can 
be interpreted as strong early signs of a reduction in breast- 
cancer mortality of at least the predicted size. Screening has 
sufficiently advanced the diagnosis, as well as or better than 
expected. Breast cancers diagnosed in this age group without 
screening are diagnosed at a worse stage than expected. 
Unfavourable side-effects, especially false-positive referrals, 
might be kept lower than those reported in other countries. 
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Nation-wide breast cancer screening at 2-yearly intervals 
started in the Netherlands around 1988, for women aged 
50-69. After extensive consultation of several advisory commit- 
tees, a completely new organization was set up with specialized 
screening units, a training programme for radiologists, radiog- 
raphers and pathologists, central and uniform quality-control 
procedures and continuous outcome evaluation. In 1991 all 
regions of the country had started screening and at the end of 
1993 70% of the target population had been invited (at least 
once). All mammographic screening trials have confirmed the 
expectation that screening for women aged 50-69 can lead to a 
reduction in breast-cancer mortality (UK Trial, 1993; Nystrom 
et al., 1993). On the basis of earlier trial results, it was expected 
that a national 3-yearly screening programme for women aged 
50-64 in the United Kingdom would yield a 25% reduction in 
breast-cancer mortality in the population invited (Wald et al., 
1991), and that a 2-yearly programme for women aged 50-69 in 
The Netherlands would yield a 22% reduction in this age 
group (de Koning et al., 1991). But can these expectations be 
confirmed'? 
A detailed cost-effectiveness (CE) analysis was performed 
earlier, indicating the expected development of effects and 
costs over time. These figures were to be used as a yardstick to 
evaluate the results of the national programme (de Koning et 
al., 1991; de Koning, 1993). The NHS programme in the 
United Kingdom has published the first results on screening 
performance (Chamberlain et al., 1993). 
The present study presents the results of the first years of the 
Dutch breast-cancer screening programme up to January 1, 
1993, including size and nodal status of the screen-detected 
cases. The results are compared with the predictions from 
the CE analysis in order to decide whether the programme 
requires any changes, at either the local or the national level. 
An analysis has been carried out on the clinical stage distribu- 
tion of all other breast cancers diagnosed. In addition, an 
attempt has been made to evaluate whether the results support 
expectations concerning a reduction in breast-cancer mortal- 
ity. 
MATERIAL AND METHODS 
For the screening programme, The Netherlands has been 
divided into 9 regions, each with a joint management board, 
consisting of regional health authorities responsible for invita- 
tion of the women and of comprehensive cancer centres 
responsible for follow-up of data from cancer patients. In each 
region, a number of specialized (static, mobile or semi-mobile) 
screening units exists. Women receive a personal letter of 
invitation (fixed date) on the basis of the municipal population 
registries. Those women who do not respond receive a re- 
minder. At the initial examination, 2-view mammography is 
performed, and at subsequent rounds 1-view. Films are devel- 
oped immediately to enable the radiographer to decide whether 
an additional (cranial-caudal) view is required because of 
technical faults or difficulty in interpretation. The mammo- 
grams are evaluated independently by 2 radiologists at the 
central unit who have to reach consensus about advising 
referral. In case of suspicion of cancer, the woman is referred 
to her general practitioner who is responsible for further 
referral to an outpatient clinic for assessment, with standard- 
ized guidelines for screen-referred women. There is no self- 
referral system in the Dutch screening programme. 
All regions use an information and registration system, and 
the regional joint management board is responsible for re- 
gional process evaluation and for reporting of regional results. 
The National Evaluation Team for Breast-cancer screening 
has defined a minimum dataset that is required for continuous 
outcome evaluation at national level. The data have been 
collected and analyzed annually by the Team since 1990. This 
report contains the data on population, invitations, screening, 
assessment and breast cancers diagnosed (by stage) in the 
years 1990-1992. Results are also reported separately for 
1990-1991 and 1992 for any time trends. The very small 
number of newly screened women in 1988-1989 (approxi- 
mately 10,000) is not taken into account here (de Koning et al., 
1991). The data are compared with the estimates from the C E  
analysis, which was based on results of the randomized 
screening trials in Sweden and the trials in The Netherlands, 
using a validated breast-cancer screening model. The model 
takes into account the natural history of the disease, current 
epidemiologic knowledge, characteristics of the screening 
programme and possible regional differences. Finally, it is used 
to predict long-term reduction in mortality from early results 
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of the programme, given estimates on improved prognosis for 
screen-detected cases obtained from randomized screening 
trials (van Oortmarssen et al., 1990; de  Koning et al., 1991; 
Boer et al., 1994). 
RESULTS 
In the year 1990, 11% of the total target population (per 
year) was invited: in 1991 and 1992 25% and 49% respectively. 
In the first years of the national programme at least 550,630 
women aged 50-69 were invited for breast cancer screening 
(Table I). Of these women, 72% took immediate action and 
attended screening, whereas 3% needed a reminder to partici- 
pate (accepted recall), The total number of women screened 
was actually 470,000; approximately 54,000 were either 49 or 
70 years old. Of the women aged 50-69, actually screened 
before January I ,  1993, 5.162 were referred for abnormalities 
suggestive of cancer. In 1,224 of these women, additional 
non-invasive procedures excluded a malignancy, while a fur- 
ther 3,713 (0.9% of screened women) underwent biopsy. In 
2,515 women (2,689 aged 49-70), breast cancer was detected 
by screening. In 3.5% of the referred women, follow-up was 
not known or no additional procedures had been performed 
(about 1% were women who refused to be registered). In 86 
cases the result of additional procedures (mostly non-invasive) 
was not yet known at time of analysis. 
These results are influenced by the fact that some women 
have been invited for subsequent screens. The regions around 
Nijmegen and Utrecht had been part of the experimental 
projects since 1974-1975. In these areas, in 1991, 60% of all 
eligible women had already been invited at least once before. 
Table I1 subdivides the results for all regions together into 
“first screen” and “subsequent screens” (having had screening 
mammography earlier in the programme or in the experimen- 
tal projects). The results for newly screened women are good: 
only 1.4% of women being referred for assessment without 
negatively influencing the detection rate (6.8 per 1,000), which 
is 3 times the clinical incidence rate (2.2 per 1,000). These 
early outcomes compare favourably with expectations. The 
expected average attendance rate of 70% is met, slightly less 
women than expected are referred and the number of screen- 
detected cancers is 5% higher than expected on the basis of 
national average incidence data. The predictive value of a 
positive screening result reaches 50%, and 67% of histologic 
examinations of biopsies show malignant lesions; both figures 
TABLE I - PERFORMANCE OF NATION-WIDE ?-YEARLY 
MAMMOGRAPHIC BREAST-CANCER SCREENING, IN THE 
NETHERLANDS FOR WOMEN AGED 50-69 
1990-1991 1992 
(A) Population and participation 
Total female population (all ages) 7,586,000 
Annual target population (50-69) 725,000 
Invited 261,827 288,803* 
Accepted call 186,457 212,132? 
Accepted recall 6,955 10.476: 
Screen positive (suspicious of 2,354 2,808 
cancer) 
Clinical mammography, ultrasound 
and/or cytology only 646 578 
Excision biopsy 1,574 2,139 
NO follow-up 134 48 
Breast cancers detected 1,068 1,447 
(B) Screening results’ 
Assessment performed; result not 43 43 
vet known 
‘Age at January l.-’Results of one region not availableinot 
included (175 screen-positives in 1991). 
are much higher than predicted on the basis of earlier Dutch 
experience. The results were quite similar in 1990, 1991 and 
1992 respectively, and the numbers are sufficiently large to 
justify the conclusions drawn. 
In contrast, relatively more women were initially being 
referred from subsequent screens without breast cancer being 
detected. The referral and detection rates in subsequent 
screens are lower than for newly screened women, as expected, 
but the predictive value of a positive screening test was “only” 
36% in 1990-1991. Although still a very favourable achieve- 
ment compared to results in many other countries, we would 
have expected it to be better than or  a t  least similar to the 
findings from first screens. The result could be explained by the 
fact that, for some of the women (mainly subsequent screens) 2 
types of referral were used: referral for biopsy in the case of 
strong suspicion of cancer, as well as advice for less invasive 
additional investigations in the case of less suspicious lesions. 
Consequently, the Table shows that the relative proportion of 
referred women who eventually needed a biopsy was much 
lower in this group. This alternative approach has been 
changed. 
Another difference from the earlier expectations relates to 
the attendance rate by age category: a constantly decreasing 
trend by age had been seen in the earlier Dutch screening 
trials, consistent in each trial and through the years. In the 
present nation-wide programme, approximately 79% of newly 
invited women aged 50-64 attended screening and only in the 
oldest 65-69 category (newly invited) did it fall to 73%. 
Screening significantly advances the diagnosis. Table 111 
compares the histology and size distribution of all 2,143 
screen-detected cancers in newly screened women (for the 
most part newly invited) to the distribution of 4,093 breast 
cancers diagnosed clinically in The Netherlands in 1989/ 1990 
in this age group, as registered in the regions through regional 
cancer registries. The 4,093 cases comprise either clinically 
diagnosed cases in 1989/90 in regions that started screening in 
1991, or all cases registered in 1990 excluding the screen- 
detected cancers in regions that had already started screening. 
Patients from the regions around Nijmegen and Utrecht with 
experimental screening projects since the seventies are not 
included among the clinical cases. 
In the screen-detected group 14% of the cancers are ductal 
carcinomas in situ, and the non-invasive and small invasive 
cancers (up to 10 mm) amount to 38%. In the clinical setting, 
the latter would have been 16% only (expected). Clearly, less 
than 20% of the screen-detected cancers are invasive and 
larger than 2 cm in diameter. Only the smallest invasive size 
category (up to 5 mm) has been detected slightly less often 
than expected. 
Another factor of importance in mortality change is that the 
national stage distribution of breast cancer in The Netherlands 
in 1989, which has become available (Netherlands Cancer 
Registry, 1992), is likely to  be less favourable than expected 
earlier on the basis of (fewer) data from non-screened, 
clinically diagnosed cases in Utrecht and Nijmegen (Table 111 
last column). 
DISCUSSION 
The results of nation-wide breast cancer screening in The 
Netherlands meet, or in some cases exceed the predictions 
made before the programme started. Since the programme is 
able to detect the expected total number of breast cancers at a 
significantly earlier stage at the first screen, the evidence 
available up to now shows the predicted reduction of 16% in 
the breast cancer mortality of the total female population to be 
realistic (de Koning el al., 1991). Invasive cancers smaller than 
11 mm in diameter or DCIS have been detected slightly more 
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TABLE I1 - OBSERVED RESULTS IN THE NATION-WIDE BREAST-CANCER SCREENING PROGRAMME FOR WOMEN AGED SO-69 IN THE 
NETHERLANDS COMPARED TO EXPECTED RESULTS, SUBDIVISION FOR FIRST SCREENS AND SUBSEQUENT SCREENS CARRIED OUT IN 1990-1992’ 
Firct screen? Suhrequent ween’ 
gpcyt$ O?;Fd Expected g:Ey$, Expected 
Screen positives (% of screened women) 1.4 1.4 1.6 0.9 0.7 0.6 
Biopsy (5% of referred women) 69.5 77.2 75 55.1 69 79 
Breast cancer detection rate (per 1,000 women screened) 6.6 6.9 6.4 3.1 3.5 3.8 
Predictive value positive screening test (referral) (%) 47.6 51 41 35.6 54.2 57 
Biopsies with malignant diagnosis (% of all biopsies) 67.8 65.6 54 63.7 76.9 72 
Lymph-node metastases (% of women with invasive screen-detected 28 33 28 28 26 24 
‘Subsequent screen = having had screening mammography before (in the rogramme or in the experimental projects).-?N = 137,708 
in 1990-1991; 177,835 in 1992.-3N = 50,029 in 1990-1991; 62,078 in 1992 &here is a small difference in absolute number of women 
screened since these are all screens performed in 1990-1991 or 1992 only, compared to accepted (re-)calls in Table I, which may have 
actually been screened in the first months of 1992 or 1993). 
REDUCTION DUETO SCREENING HAD BEENcALCUL.AT.ED 
~ ~ ~~ ~ . . 
Clinically 
diagnosed (1st) screen-detected 
Observed Observed Expected Ohsewed Expected 1 wn-I 99 I 1992 
DCIS (ductal carcinoma in situ) 13.0 13.9 11.3 4.0 4.2 
Tla  (invasive 2 5 mm) 3.6 4.3 8.1 1.4 4.1 
T2+ (invasive > 20 mm) 16.9 19.8 19.7 50.1 42.7 
Txinot (vet) classified 5.6 8.4 5.6‘ 7.9 7 9’ 
T l b  (invasive 6-10 mm) 22.0 19.1 16.6 6.1 7.7 
Tlc (invasive 11-20 rnrn) 38.9 34.5 38.7 30.5 33.4 
’ I f  same % taken into account as observed (in 1990-1991). 
frequently than expected. These results also fulfil the tentative 
guidelines on detection rate, tumour size and nodal status, as 
put forward on the basis of the results in Kopparbergl 
Ostergotland (Tabir et al., 1992). The small discrepancy 
regarding invasive cancers smaller than 5 mm in observed 
compared to expected percentages, in both screen-detected 
and clinically diagnosed cases, is likely to be due to classifica- 
tion problems during the ’70-’80s in the Dutch trials. 
In the years to come, more and other data arc to be 
expected. Information about interval cancer rates from the 
nationally covered cancer registry(ies) as compared to the 
predicted rates will give a firm basis to decide whether the 
programme is able to detect a substantial proportion of all 
scrcen-detectable pre-clinical breast cancers. It already ap- 
pears unlikely, from the detection rates and the size/histology 
distribution of screen-detected cases, that the interval cancer 
rate will be much different from that expected. It is not yet 
clear whether interval cancers will in general have a worse 
prognosis (Tabar et al., 1987; Ikeda et al., 1992), but with these 
first results presented, this is not expected to significantly 
influence the results on mortality reduction. 
The first results are satisfying for several reasons. The 
invitation system is based on (100% covered) municipal 
population registries and recall of non-participants. The low 
referral rates, combined with the high predictive value of a 
referral, show that the number of false positives can be 
minimized, thus refuting one of the principal objections raised 
by opponents of screening. Unfavourable consequences are 
apparently being limited, due to strict criteria for referral. In 
that respect, the results compare favourably with those of 
other countries where generally a 4-7% referral rate is found 
(Chamberlain et al., 1993), although it should be noted that 
2-view mammography is used in the Dutch programme. Our 
results, like the regional UK results, indicate that high detec- 
tion rates are not dependent upon relatively high referral 
rates. The impact on workload and cost is proportionally 
lower. The higher UK referral rate, if reproduced in the 
Netherlands, would cause an extra 2 million Dutch guilders 
($1.2 million) annually for cost of assessment. 
This analysis shows that the routine application of mammo- 
graphic screening can attain quality levels that are comparable 
to those in experimental screening trials. We think that the use 
of specialized screening centres, the gradual build-up of the 
programme and the establishment of a National Expert and 
Training Centre for Breast Cancer Screening for the improve- 
ment of personnel and quality control have been decisive in 
attaining this result, together with the fact that extensive 
“reference” predictions were available beforehand. 
These early results do not make a continuous monitoring 
and continuous adjustment of predictions superfluous. These 
first years have already shown the need for interpreting 
regional differences in order to keep one uniform, high-quality 
programme running throughout the country. In the build-up 
period, in particular, it is important to learn from regional 
policies, for instance regarding invitations to see which one 
produces relatively high attendance rates. In this phase adapta- 
tions can still be made and useful advice for new screening 
centres given. More importantly, it will take years before a 
significant impact on breast cancer mortality can be expected 
and any reduction may be partly obscured by “autonomous” 
mortality changes. The small decrease in breast cancer mortal- 
ity visible in Sweden since 1980-1984 (La Vecchia et al., 1992) 
may be due to the large number of Swedish screening trials on 
hand since the seventies, but it is not conclusive without 
information on stage distributions of all breast cancers diag- 
nosed, screen-detected or not, and on changes in adjuvant 
systemic treatment policy for all women with breast cancer 
diagnosed. It should be emphasized, also, that breast cancer 
screening is not an easy “export product” (Beemsterboer efal . ,  
1994). Under optimal conditions, the balance between favour- 
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able and unfavourable effects for the participating women will 
tip toward the former and the cost-effectiveness ratio will be 
relatively favourable compared to other health care provisions. 
But in countries with a lower breast-cancer incidence, with 
different health-care systems or  without the possibility of 
maintaining very high quality standards, the cost-effectiveness 
ratio may be much higher and, especially when high quality 
standards cannot be guaranteed, breast-cancer screening there 
might still do more harm than good. 
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